Changing clinical practice in rare diseases through innovative trial designs: the CAPTIVATE node

What we will do:
We will create a group of researchers that will develop better ways to test new medicines for people with rare diseases in clinical trials. We want to find ways that need as few people to take part as possible, that are quicker and that provide all the information needed for the authorities to approve a new medicine to be prescribed to people with rare diseases from one single trial. The group of researchers will be called 'the CAPTIVATE node' and people living with rare conditions will contribute to the research.

Why we are doing this:
People with rare diseases expect to receive treatments which have been approved for use in the NHS based on evidence from trials. It is hard to do trials in rare diseases because there may only be a few people affected with the disease who are able to take part. It is also hard to expect people to take a 'dummy' medicine (placebo) as part of randomised controlled trials. There is another method called Bayesian clinical trials (named after a scientist called Thomas Bayes). This method may be useful in trials in rare diseases because it is more flexible. The method allows us to learn about medicines being tested in the trial by analysing results from one patient at a time rather than waiting to the end of the trial. This can help reduce the number of people needed to take part. The method also allows us to look at any information that already exists about the medicine being tested. We can use this when we study the results of the trial.

How we will do it:
We will develop ways to test medicines in a single trial (a 'one-stop-study') that collects all the data needed for approval in one go. We will explore how best to include the information about a medicine that is already known. This way, trial results are more likely to be accepted by healthcare professionals, people living with rare diseases and the authorities who set the rules for approving new medicines. We will work on trials in children, where it is so...